We plan to use other AD models, such as 3 × Tg‐AD mice, which exhibit both Aβ and tau pathologies, and to evaluate the effects of 9‐MF against tau‐related neurotoxicity in these models. This evidence concerns the gene MAPT and Alzheimer disease.